Phenothiazine diaminium salts and their use
View Patent ↗The invention relates to compounds of general formula (I): wherein: each of R 1 and R 9 is independently selected from: —H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl; each of R 3NA and R 3NB is independently selected from: —H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl; each of R7NA and R7NB is independently selected from: —H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl; and wherein: each of R A and R B is independently selected from: C 1-4 alkyl, halogenated C 1-4 alkyl, and C 6-10 aryl; or R A and R B are linked to form a group selected from: C 1-6 alkylene and C 6-10 arylene; and pharmaceutically acceptable salts thereof, which are useful in the treatment of, for example, Alzheimer's disease. In other aspects the invention also relates to novel formulations of 3,7-diamino-10H-phenothiazinium salts.
1. A method of treating a tauopathy comprising administering to a subject in need thereof the compound of the following formula:
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
2. The method of claim 1 , wherein the tauopathy is Alzheimer's disease (AD), Pick's disease, progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), FTD with parkinsonism linked to chromosome 17 (FTDP 17), frontotemporal lobar degeneration (FTLD) syndromes; disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC), pallido-ponto-nigral degeneration (PPND), Guam-ALS syndrome, pallido nigro luysian degeneration (PNLD), cortico-basal degeneration (CBD), dementia with argyrophilic grains (AgD), dementia pugilistica (DP) or chronic traumatic encephalopathy (CTE), Down's syndrome (DS), dementia with Lewy bodies (DLB), subacute sclerosing panencephalitis (SSPE), Niemann-Pick disease, type C (NPC), Sanfilippo syndrome type B, mucopolysaccharidosis III B (MPS III B)), or myotonic dystrophies (DM), DM1 or DM2.
3. The method of claim 2 , wherein the tauopathy is Alzheimer's disease.
4. The method of claim 2 , wherein the tauopathy is PSP.
5. The method of claim 2 , wherein the tauopathy is FTD, FTDP-17, or FTLD.